As of November 2016, 33 states and the District of Columbia legally allow cannabis for personal medical use. Rules surrounding the use of medical cannabis (medical marijuana) vary by state. The first state in the union to legalize the medical use of marijuana was California in 1996. States that allow medical marijuana include: Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, North Dakota, New York, Ohio, Oregon, Pennsylvania, Rhode Island, Utah, Vermont, Washington, and the District of Columbia. It is important to recognize that these state marijuana laws do not change the fact that using marijuana continues to be an offense under Federal law.
Well, primarily because it’s just simpler to get. Because it’s legal, it can be ordered right online without a rpescription. Second, many people prefer the natural aspect of CBD oil found in hemp, which doesn’t need to be coaxed or altered in order to derive high levels of CBD from it. CBD oil from hemp is pure, which means the levels of THC and other trace compounds are miniscule. That means you can count on getting the effects of CBD without experiencing unwanted side effects. And finally, because hemp-derived CBD oil has been used for so long medicinally, many people trust it more than CBD oil from hybridized pot strains, which have only recently begun to be explored as a medicinal product.
This content is strictly the opinion of Dr. Josh Axe and is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. Neither Dr. Axe nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this educational content. All viewers of this content, especially those taking prescription or over-the-counter medications, should consult their physicians before beginning any nutrition, supplement or lifestyle program.
In response to the FDA’s historic decision, the Drug Enforcement Administration (DEA) announced in September 2018 that it had removed Epidiolex from Schedule I classification, a category reserved for dangerous drugs with no medical value. Henceforth, Epidiolex would be considered a Schedule V drug, the least dangerous designation under the Controlled Substances Act.
CBD has some other very important jobs outside of the endocannabinoid system (ECS). For instance, CBD mildly activates one of the brain’s predominant serotonin receptors (5-HT1A), which may explain CBD’s effects on depression and anxiety. It also acts at the peroxisome proliferator activated receptors (PPARs), which halt the proliferation of cancer cells and convey neuro- and cardioprotection. By interacting with a particular PPAR (gamma), CBD could prove to be a promising new way to prevent alzheimer’s disease and other brain disorders.

CBD has shown therapeutic efficacy in a range of animal models of anxiety and stress, reducing both behavioral and physiological (e.g., heart rate) measures of stress and anxiety.xxxiii,xxxiv In addition, CBD has shown efficacy in small human laboratory and clinical trials. CBD reduced anxiety in patients with social anxiety subjected to a stressful public speaking task.xxxv In a laboratory protocol designed to model post-traumatic stress disorders, CBD improved “consolidation of extinction learning”, in other words, forgetting of traumatic memories.xxxvi The anxiety-reducing effects of CBD appear to be mediated by alterations in serotonin receptor 1a signaling, although the precise mechanism remains to be elucidated and more research is needed.xxxvii
The existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See Sativex Commences US Phase II/III Clinical Trial in Cancer Pain and GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome ).
Of the many developmental disorders, autism and its associated spectrum of disorders are perhaps the most pervasive. Autistic children suffer from insomnia, irritability and a loss of appetite, to name a few. Practitioners have been experimenting with the use of CBD oil in curtailing the social anxiety and psychological manifestations vicariously caused in victims of autism.
For reasons discussed previously, despite its molecular similarity to THC, CBD only interacts with cannabinoid receptors weakly at very high doses (100 times that of THC),xl and the alterations in thinking and perception caused by THC are not observed with CBD.iii.iv,v The different pharmacological properties of CBD give it a different safety profile from THC.

Thank you for your questions. Marijuana and hemp are two extremely different strains of the same cannabis sativa plant that have been bred over thousands of years to have entirely different purposes. (Hemp is not the male version of the marijuana plant.) They both contain CBD. Hemp only contains CBD whereas marijuana contains CBD and perhaps a hundred or so other chemicals with a variety of functions, such as THC, the molecule that makes people “high”. Any medicine can have different effects on different people. For example, Benadryl makes some people sleepy yet can make others wide-awake. So, it is not inconsistent for a particular medicine to cause a symptom in one person and to help alleviate it in another. So while many people experience relaxation with CBD, so people do experience the “paradoxical” effect of irritability.


Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol.Res. 2010;32(5):451-459. View abstract.
Cutting-edge science has shown that the endocannabinoid system is dysregulated in nearly all pathological conditions. Thus, it stands to reason that “modulating endocannabinoid system activity may have therapeutic potential in almost all diseases affecting humans,” as Pal Pacher and George Kunos, scientists with the U.S. National Institutes of Health (NIH), suggested in a 2014 publication.
×